TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12470424
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HAI of melphalan (50 mg) and activated leukocytes
Study: 12470424
Drug: HAI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI of melphalan (50 mg) alone
Study: 7864411
Drug: Enalaprilat (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (0.06 mg/kg)
Study: 25698370
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (125 mg/week)
Study: 28822046
Drug: Intravenous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous abatacept (10 mg/kg/month)
Study: 28822046
Drug: Subcutaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous and Intravenous abatacept
Study: 20947593
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 µg kg⁻¹ (R0.5 group, n=24)
Study: 20947593
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 µg kg⁻¹ (R1.0 group, n=24)
Study: 20947593
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of remifentanil
Study: 15553818
Drug: Compound Salvia
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Salvia injection (CSI) plus conventional treatment of western medicine
Study: 29546692
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement of 4000 IU for 3 years
Study: 19875974
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by adjuvant treatment with tegafur-uracil (UFT)
Study: 16773286
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (prep group)
Study: 16773286
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (non-prep group)
Study: 15296809
Drug: Hormone-Replacement Therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-Replacement Therapy (HRT) component
Study: 10936836
Drug: Infiltration anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration anesthesia with 3.6 mL of lidocaine with 1:80,000 epinephrine (L-E)
Study: 2906476
Drug: olsalazine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: olsalazine, 3 g/day
Study: 2906476
Drug: sulphasalazine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphasalazine, 3 g/day
Study: 28740945
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration Exercises twice per week (WBVE2)
Study: 12372097
Drug: Aloesin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloesin treatment (administered four times a day for 15 days)
Study: 12372097
Drug: Arbutin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbutin treatment (administered four times a day for 15 days)
Study: 12372097
Drug: Aloesin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloesin and arbutin cotreatment (administered four times a day for 15 days)
Study: 12372097
Drug: Aloesin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloesin treatment (dose-dependent)
Study: 6366138
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment strategy
Study: 2470000
Drug: Dose reductions
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reductions and interval prolongations
Study: 1096275
Drug: Prenazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenazone 600 mg
Study: 1096275
Drug: Aspirin 4
Normalized name: aspirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 4 g daily
Study: 31076856
Drug: B-vitamin supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplementation (folic acid 400 µg and vitamin B12 500 µg)
Study: 27828579
Drug: Cognitive-motor physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-motor physiotherapy intervention (4 months, single weekly visit)
Study: 25104582
Drug: 3g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of sea buckthorn (SB) oil daily
Study: 17963431
Drug: MN 001
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN 001 (750 mg twice daily)
Study: 17963431
Drug: MN 001
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN 001 (500 mg three times daily)
Study: 11449671
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of argatroban (10 mg/day, three times a week)
Study: 9482129
Drug: verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: verapamil SR 240 mg (V)
Study: 9482129
Drug: amiloride 5
Normalized name: amiloride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amiloride 5 mg + hydrochlorothiazide 50 mg (AH)
Study: 8304488
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion to maintain plasma ANG II levels at around basal values (6.6 ± 1.6 pmol/l)
Study: 8304488
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of aldosterone (previous study)
Study: 10077777
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg b.i.d. for 10 days)
Study: 10077777
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (250 mg b.i.d. for 10 days)
Study: 7586944
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of 5 mg atipamezole hydrochloride
Study: 7586944
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of 10 mg atipamezole hydrochloride
Study: 7586944
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of 20 mg atipamezole hydrochloride
Study: 7586944
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of 40 mg atipamezole hydrochloride
Study: 7586944
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 20 mg atipamezole hydrochloride
Study: 7586944
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg atipamezole hydrochloride
Study: 31838561
Drug: Oral-VRL (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-VRL (60 mg/m2 for cycle 1, 80 mg/m2 for cycles 2-6) + EPI (75 mg/m2 on day 1 for all cycles)
Study: 31838561
Drug: IV-VRL (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-VRL (25 mg/m2 for cycle 1, 30 mg/m2 for cycles 2-6) + EPI (75 mg/m2 on day 1 for all cycles)
Study: 27044546
Drug: Clarithromycin at
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin at 1 g daily for three consecutive days
Study: 25540273
Drug: HPV-16/HPV-18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/HPV-18 AS04-adjuvanted vaccine
Study: 16600938
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy density complementary foods (1.5 kcal/g)
Study: 16600938
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy density complementary foods (0.4 kcal/g)
Study: 10807483
Drug: Titrated RUL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated RUL ECT at 2.25 times initial seizure threshold (mean dose, 136 mC)
Study: 10807483
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose RUL ECT at 403 mC
Study: 9026840
Drug: lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (20 mg/day)
Study: 8099492
Drug: alpha 1‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha 1‐adrenergic blocker doxazosin (2 mg/day)
Study: 22614285
Drug: Intravesical hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical hyaluronic acid (HA) 800 mg and chondroitin sulfate (CS) 1 g in 50 mL of saline solution once weekly for 4 weeks then once every 2 weeks twice more (group 1)
Study: 22614285
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term antibiotic prophylaxis using sulfamethoxazole 200 mg and trimethoprim 40 mg once weekly for 6 weeks (group 2; control)
Study: 18713150
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antimicrobial treatment)
Study: 11752105
Drug: Edrophonium (0.01-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.01-1.0 mg/kg)
Study: 11752105
Drug: Edrophonium (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.2-0.4 mg/kg)
Study: 11752105
Drug: Edrophonium (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (1.0 mg/kg)
Study: 804397
Drug: Parenteral carbohydrates
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral carbohydrates combined with essential amino acids and histidine
Study: 27661192
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (20 IU)
Study: 23398227
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum treatment
Study: 17188609
Drug: Intravenous Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Glucose Tolerance Test (IVGTT)
Study: 12023757
Drug: Polymethylmethacrylate (PMMA)
Normalized name: methylmethacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymethylmethacrylate (PMMA) implant
Study: 9855418
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccines
Study: 8011010
Drug: Ketorolac (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (10 mg every 6 h)
Study: 8011010
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (50 mg every 8 h)
Study: 2492166
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone‐releasing factor (GH‐RF) (1 microgram/kg i.v.)
Study: 1096540
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg per day of temazepam
Study: 31055542
Drug: Pranayama breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranayama breathing exercises for 15 minutes daily for 1 month
Study: 21670470
Drug: Fludarabine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cyclophosphamide, and rituximab (as salvage therapy)
Study: 18198776
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of tenoxicam 20 mg
Study: 18198776
Drug: Oral tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenoxicam 20 mg a day for 10 days
Study: 15051552
Drug: Ginger (1.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1.05 g daily for 3 weeks)
Study: 15051552
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (75 mg daily for 3 weeks)
Study: 9690699
Drug: Flutamide (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (a selective androgen receptor antagonist)
Study: 7516637
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) 100 mg/mq i.v. on day 1 and 5-fluorouracil (5-FU) 750 mg/mq/day i.v. continuous infusion from days 1 to 4
Study: 7516637
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) 100 mg/mq i.v. on day 1 and 5-fluorouracil (5-FU) 750 mg/mq/day i.v. continuous infusion from days 1 to 4 with added alpha interferon (IFN-alpha) 3 MU s.c., three times weekly from days 1 to 21
Study: 7516637
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) and 5-fluorouracil (5-FU) with recombinant granulocyte colony stimulating factor (G-CSF) 5 micrograms/kg b.w. s.c. from days 7 to 18
Study: 2815647
Drug: Millimetric waves
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimetric waves treatment
Study: 31852711
Drug: 3-month dual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month dual antiplatelet therapy (DAPT)
Study: 31888702
Drug: Buzhong Yiqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buzhong Yiqi decoction plus standard therapy
Study: 25963758
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate with single dose of calcium gluconate (SBCG1)
Study: 25963758
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate with double dose of calcium gluconate (SBCG2)
Study: 16642484
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at IMIP (Recife, Brazil)
Study: 16642484
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at US centers
Study: 14731162
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors (ritonavir or indinavir)
Study: 28547269
Drug: Continuous bladder
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bladder catheterization (CC)
Study: 20167144
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 1 (96 actuations, 24 days)
Study: 20167144
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 2 (120 actuations, 30 days)
Study: 20167144
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 3 (128 actuations, 32 days)
Study: 20167144
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI without actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Run-in period
Study: 18062023
Drug: Combined electric,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined electric, electromagnetic, quantum and microvibration therapy with basic treatment (antiaggregants, beta-blockers, statins)
Study: 18062023
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy with basic treatment (antiaggregants, beta-blockers, statins)
Study: 18062023
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment without physiotherapy
Study: 12134936
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml of 1% lidocaine injected into the carotid sinus nerve
Study: 12134936
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection of lidocaine
Study: 11574360
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg propofol
Study: 4061377
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg I.V. before therapy, and 4 mg I.V. q 4 h X 6 doses)
Study: 30045185
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXC 001 (5 mg/cm)
Study: 20870113
Drug: Intracameral phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral phenylephrine 15.0 mg/mL (1.5%)
Study: 20870113
Drug: Intracameral phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral phenylephrine 30.0 mg/mL (3.0%)
Study: 20870113
Drug: Intracameral phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral phenylephrine 0.15 to 5.00 mg/mL (0.015% to 0.500%)
Study: 16615926
Drug: High-dose magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose magnesium sulfate (50 mg/kg load and 2 g/h)
Study: 16615926
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium sulfate (25 mg/kg load and 1 g/h)
Study: 16615926
Drug: High-dose magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose magnesium sulfate
Study: 16615926
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium sulfate
Study: 229707
Drug: FOY-305 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOY-305 oral capsule
Study: 25752903
Drug: Group BII:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BII: Initial bolus plus early start of the intermittent infusion
Study: 25752903
Drug: Group DII:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group DII: No bolus plus delayed start (8 h) of the intermittent infusion
Study: 23635846
Drug: CBTp (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTp (Cognitive Behavioural Therapy) + TAU (Treatment as Usual)
Study: 10718501
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for aspirin)
Study: 9197297
Drug: 2-chloroprocaine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-chloroprocaine 1% (30 ml)
Study: 9197297
Drug: 2-chloroprocaine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-chloroprocaine 3% (10 ml)
Study: 3569828
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 5% tylose
Study: 3569828
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 2.5 mM calcium chloride gel
Study: 3569828
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 9.0 mM calcium chloride gel
Study: 3569828
Drug: calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium chloride gel
Study: 29627621
Drug: Buprenorphine/naloxone (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (flexible take-home doses)
Study: 29627621
Drug: Methadone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (daily witnessed ingestion)
Study: 12699023
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy and nicotine patch
Study: 10226092
Drug: Beta-blockers and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers and amiodarone
Study: 10226092
Drug: Beta-blockers alone
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers alone
Study: 10226092
Drug: Neither beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither beta-blockers nor amiodarone
Study: 8688255
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine at 6 ml h‐1
Study: 8688255
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine at 8 ml h‐1
Study: 8688255
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine at 10 ml h‐1
Study: 8688255
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine at 12 ml h‐1
Study: 8688255
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine at 14 ml h‐1
Study: 8688255
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no postoperative extradural infusion)
Study: 8688255
Drug: All ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All ropivacaine infusion groups
Study: 8688255
Drug: Higher ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher ropivacaine infusion rates
Study: 18774743
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (DA) as monotherapy
Study: 18774743
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (DA) as adjunctive therapy
Study: 18774743
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (DA)
Study: 17335818
Drug: N‐acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐acetyl cysteine (1.8 g/d)
Study: 15470328
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rabeprazole once daily
Study: 15470328
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabeprazole twice daily
Study: 15470328
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rabeprazole 4 times daily